Skip to main content

Table 1 Predicted costs and effectiveness outcomes

From: Implementation of methadone therapy for opioid use disorder in Russia – a modeled cost-effectiveness analysis

  MT supplied to 3.1% of OUD population MT supplied to 12.5% of OUD population MT supplied to 25% of OUD population MT supplied to 55% of OUD population  
Year DALYsaAverted Costa,b DALYsaAverted Costa,b DALYsaAverted Costa,b DALYsaAverted Costa,b Cost/DALY Averteda,b
1 6,562 2,145,882 26,458 8,652,750 52,916 17,305,500 116,415 38,072,100 327
2 6,148 2,034,130 24,810 8,208,772 49,674 16,435,185 109,568 36,250,553 331
3 5,759 1,928,198 23,262 7,787,574 46,626 15,608,638 103,115 34,516,158 335
4 5,395 1,827,783 21,808 7,387,988 43,759 14,823,660 97,034 32,864,744 339
5 5,053 1,732,597 20,441 7,008,905 41,064 14,078,160 91,304 31,292,342 343
6 4,731 1,642,368 19,158 6,649,274 38,531 13,370,151 85,905 29,795,170 347
7 4,430 1,556,838 17,953 6,308,095 36,149 12,697,749 80,819 28,369,630 351
8 4,147 1,475,762 16,822 5,984,422 33,910 12,059,164 76,027 27,012,295 356
9 3,882 1,398,908 15,759 5,677,358 31,806 11,452,693 71,512 25,719,901 360
10 3,633 1,326,057 14,762 5,386,049 29,829 10,876,723 67,260 24,489,341 365
Present value 49,739 17,068,524 201,234 69,051,186 404,265 138,707,623 898,958 308,382,234 343
  1. aDiscounted at 3% after year 1; b2015 US Dollars